Management has said since Feb that commencement of Phase III clinical trial in Europe is aiming to be in 2H of CY2021. Who knows we may overshoot that into next year, but I still think the market is severely overestimating the effect of the FDA not approving us for 1 phase III trial with a primary endpoint of ICP reduction or headache days, the fact still remains that we are approved in EU which presents significant upside in the medium to long term.
Ann: Appendix 4E and Annual Report, page-60
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.335M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14158 | 7.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 19000 | 2 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable